Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?
Authors
Keywords
-
Journal
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
Volume 55, Issue 7, Pages 466-479
Publisher
Informa UK Limited
Online
2018-10-03
DOI
10.1080/10408363.2018.1499706
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
- (2017) James L. Gulley et al. JNCI-Journal of the National Cancer Institute
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
- (2017) Christopher Abbosh et al. NATURE
- Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies
- (2017) David J. Byun et al. Nature Reviews Endocrinology
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy
- (2017) Giulia Viale et al. Biomed Research International
- Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
- (2017) James L. Gulley et al. JNCI-Journal of the National Cancer Institute
- Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
- (2017) Sacha Gnjatic et al. Journal for ImmunoTherapy of Cancer
- Autoantibody Production in Cancer—The Humoral Immune Response toward Autologous Antigens in Cancer Patients
- (2016) P. Zaenker et al. AUTOIMMUNITY REVIEWS
- Cancer immunotherapy: the beginning of the end of cancer?
- (2016) Sofia Farkona et al. BMC Medicine
- Management of toxicities of immune checkpoint inhibitors
- (2016) Lavinia Spain et al. CANCER TREATMENT REVIEWS
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
- (2016) Douglas B. Johnson et al. Nature Communications
- Novel technologies and emerging biomarkers for personalized cancer immunotherapy
- (2016) Jianda Yuan et al. Journal for ImmunoTherapy of Cancer
- Cancer Mutational Load: The More the Merrier for Immune Checkpoint Blockade Therapies
- (2016) EBioMedicine
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- Validation of New Cancer Biomarkers: A Position Statement from the European Group on Tumor Markers
- (2015) M. J. Duffy et al. CLINICAL CHEMISTRY
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Delineating monoclonal antibody specificity by mass spectrometry
- (2015) Dimitrios Korbakis et al. Journal of Proteomics
- Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer
- (2015) Victoria Doseeva et al. Journal of Translational Medicine
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
- (2015) Alexander Faje Pituitary
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
- (2014) Ester Simeone et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Classifying Patients for Breast Cancer by Detection of Autoantibodies against a Panel of Conformation-Carrying Antigens
- (2014) R. L. Evans et al. Cancer Prevention Research
- Present and future of cancer biomarkers
- (2014) Eleftherios P. Diamandis CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- A repository for “rare” tumor markers?
- (2014) Eleftherios P. Diamandis CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
- (2014) Mabel Ryder et al. ENDOCRINE-RELATED CANCER
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-associated autoantibodies as diagnostic and prognostic biomarkers
- (2013) Chang-Kyu Heo et al. BMB Reports
- Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab
- (2013) Jeffrey S. Weber et al. CANCER
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy
- (2013) L Qin et al. Blood Cancer Journal
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients
- (2012) S. S. Kwek et al. JOURNAL OF IMMUNOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
- (2011) Omid Hamid et al. Journal of Translational Medicine
- Predictive biomarkers: a paradigm shift towards personalized cancer medicine
- (2011) Nicholas B. La Thangue et al. Nature Reviews Clinical Oncology
- Cancer immunotherapy – revisited
- (2011) W. Joost Lesterhuis et al. NATURE REVIEWS DRUG DISCOVERY
- Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
- (2011) J. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
- (2010) Geoffrey Y. Ku et al. CANCER
- Gene Signature in Melanoma Associated With Clinical Activity
- (2010) Thomas F. Gajewski et al. CANCER JOURNAL
- Autoantibodies to Tumor-Associated Antigens as Cancer Biomarkers
- (2010) P. Belousov et al. CURRENT MOLECULAR MEDICINE
- Seromic profiling of ovarian and pancreatic cancer
- (2010) S. Gnjatic et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Predictive and prognostic molecular markers for cancer medicine
- (2010) Sunali Mehta et al. Therapeutic Advances in Medical Oncology
- Serum autoantibodies as biomarkers for early cancer detection
- (2009) Hwee Tong Tan et al. FEBS Journal
- Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy
- (2009) Marianna Sabatino et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search